GapSummit 2022 w/ Dr Dave Michalovich

Dave will be speaking on the “The Quantified Self Panel”, which aims to generate interesting and engaging discussions covering topics such as; 

  • How to deal with, communicate, and successfully utilise large datasets efficiently to advance healthcare research?
  • How can we benefit from digital technologies in precision healthcare, and what are the pitfalls that need addressing?
  • How do we harmonise big data with the definitions of clinical phenotypes and diagnosis?
  • How do we ensure equitable access to genomics-based technologies?
  • What impact on innovation would you most like to see, or are most excited about, regarding multi-omics datasets? 
Speakers on the panel include:
  • Prof Sir Mark Caulfield - VP for Health, Queen Mary University of London
  • Robert W Kotchie -President, Real World Solutions, IQVIA
  • Sir Harpal Kumar - President, BioPharma Business & Europe GRAIL, LLC
  • Dr Dave Michalovich - SVP Precision Medicine, BenevolentAI
  • Leanne Summers - Head of AI Strategy, NHS Transformation Directorate
Event website →

Dave Michalovich

VP Precision Medicine

Dave is responsible for driving the Precision Medicine strategy at BenevolentAI, taking a patient-centric approach to understand disease endotypes, mechanisms and targets. Prior to joining BenevolentAI Dave was a Senior Scientific Director at GSK where he led discovery teams in the Adaptive Immunity Research Unit and Respiratory TA.

More Posts

You Might Also Like

Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022